# A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

> **NCT02022501** · PHASE1,PHASE2 · COMPLETED · sponsor: **Santen Inc.** · enrollment: 10 (actual)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** DE-120

## Key facts

- **NCT ID:** NCT02022501
- **Lead sponsor:** Santen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2016-04-21
- **Final completion:** 2016-04-21
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02022501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02022501, "A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02022501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*